Table of Contents
Patients that suffer from Type 2 diabetes rely on insulin and other medications to help control their blood glucose levels. If a patient were to lose control of their blood glucose levels, the patient’s likelihood of dying from Type 2 diabetes significantly increases. As a solution for patients with Type 2 diabetes, Johnson & Johnson created a sodium-glucose co-transporter 2 (SGLT2) inhibitor called Invokana®. SGLT is the protein responsible for the reabsorption of glucose in the kidneys. By stopping this protein from being absorbed, Invokana was designed to help stabilize the patient’s blood sugar.
Why are patients speaking to the Hollis Law Firm about Invokana lawsuits?
Although Invokana helps stop the reabsorption of glucose in the kidneys, Invokana has been linked to the development of diabetic ketoacidosis (DKA). DKA occurs whenever the patient’s body cannot use glucose as a fuel source because there is a lack of insulin in the body. DKA is a serious medical condition and many patients may suffer death. In May 2015, the U.S. Food and Drug Administration took action and issued an official warning regarding Invokana.
If you or your loved one have suffered from DKA as a result of taking Invokana, you may want to speak to the Hollis Law Firm about a potential Invokana lawsuit. The professional and caring staff at the Hollis Law Firm is experienced in helping those who have fallen victim to harmful drugs. It is important to get all the facts about recent Invokana lawsuits. Speak to a member of the Hollis Law Firm today to help you determine if your case may be eligible for compensation. To contact a member of the Hollis Law Firm about your unique case, fill out the form located on this page. If you wish to speak over the phone with an experienced member at the Hollis Law Firm, call 1-800-701-3672 for your free case evaluation.